Related Experiment Video
Updated: Jul 5, 2026

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
General health status and adherence to antiretroviral therapy
Roberto Cardarelli1, Stephen Weis, Elvin Adams
1Primary Care Research Institute, University of North Texas Health Science Center, Fort Worth, USA. rcardare@hsc.unt.edu
Unlabelled:
Highly active antiretroviral therapy (HAART) adherence is crucial in lowering HIV/AIDS-related mortality. General health status is known to predict mortality, but no study has assessed its association with HAART adherence. A total of 103 whites, African Americans, and Hispanic/Latinos with HIV/AIDS underwent an interview using validated measures. Regression analyses assessed the relationship between general health status and HAART adherence while controlling for social support, sense of control, depression, stress, HIV stigma, substance abuse, and unfair treatment because of race. Those rating their general health as fair/poor were 4 times more likely to be nonadherent (odds ratio [OR], 4.34; 95% confidence interval [CI], 1.19-15.79). This association dramatically strengthened in the multivariate regression model (OR, 10.96; 95% CI, 1.46-82.36) after controlling for the covariates.
Conclusion:
General health status was the strongest predictor of HAART nonadherence, and future research is needed to assess whether this 1-question general health measure can be clinically used to influence adherence.
Related Concept Videos
Retrovirus Life Cycles
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Therapeutic Drug Monitoring: Affecting Factors
Sexually Transmitted Infections
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Bioavailability Study Design: Healthy Subjects Versus Patients

